Vulnerability, social value and the equitable sharing of benefits from research: beyond the placebo and access debates
The vulnerability of research participants is a critical topic for the 2024 revision of the Declaration of Helsinki, with the proposal to include "social value. " However, this proposal has been withdrawn and the relationship between the two concepts has not been clarified. This paper attempts to clarify: (1) the recent reform for the ethical inclusion of vulnerable study participants to promote diversity; (2) the social value, prerequisite for everyone, especially for those who are vulnerable and the most in need; (3) the requirements for promoting the inclusion of vulnerable participants, in particular the review of the norms for placebo-controlled trials and post-trial access; (4) finally, the direction of research ethics reform to achieve social value and equitable global health.
Authors
- Kotone Matsuyama (ORCID: https://orcid.org/0000-0003-4390-0984)
- Dirceu Bartolomeu Greco (ORCID: https://orcid.org/0000-0002-4419-5634)
- Chieko Kurihara (ORCID: https://orcid.org/0000-0002-0792-7955)
- Ames Dhai
- Varvara Baroutsou
Institutions
- Universidade Federal de Minas Gerais (BR)
- University of the Witwatersrand (ZA)
- Kanagawa Dental University (JP)
- International Pharmaceutical Federation (NL)
- Nippon Medical School (JP)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2024-09-17
- DOI
- https://doi.org/10.3389/fmed.2024.1432267
- Citations
- 7
- Primary Topic
- Ethics in Clinical Research
- Type
- article
- Field-Weighted Citation Impact
- 3.80
Funders
- Associação Médica Brasileira